The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4.sup.+ helper T cells and CD8.sup.+ cytotoxic T cells, respectively. Preferably, the antigen recognized by CD4.sup.+ helper T cells is a molecule identified by the SEREX method and that recognized by CD8.sup.+ cytotoxic T cells is a tumor-specific antigen, tumor-associated antigen or cell-associated antigen. Furthermore, so that the antigens recognized by CD4.sup.+ helper T cells and CD8.sup.+ CTL are expressed and presented on the same cell, the expression vectors preferably are immobilized on the same gold particle and administered into the cell by gene gun; however, this invention is not restricted thereto. The vaccine can also be used as a pharmaceutical agent.